Patent Number: 6,310,185

Title: Recombinant human anti-Lewis Y antibodies

Abstract: The invention provides for the production of several humanized murine antibodies specific for the antigen Lewis Y, which is recognized by murine atibodies specific for the Lewis Y antigen. The Lewis Y antigen is expressed in normal tissues but the level of expression is higher in certain tumour types so that the antigen can be used as a marker for cells of some breast, colon, gastric, esophageal, pancreatic, duodenal, lung, bladder and renal carcinomas and gastric and islet cell neuroendocrine tumours. The invention also provides for numerous polynucleotide encoding humanized Lewis Y specific antibodies, expression vectors for producing humanized Lewis Y specific antibodies, and host cells for the recombinant production of the humanized antibodies. The invention also provides methods for detecting cancerous cells (in vitro and in vivo) using humanized Lewis Y specific antibodies. Additionally, the invention provides methods of treating cancer using humanized Lewis Y specific antibodies.

Inventors: Wallace; Thomas P. (Methlick, GB), Armour; Kathryn Lesley (Aberdeen, GB), Carr; Francis Joseph (Balmedie, GB), Old; Lloyd J. (New York, NY), Stockert; Elisabeth (New York, NY), Welt; Sydney (New York, NY), Kitamura; Kunio (New York, NY), Garin-Chesa; Pilar (Biberach, DE)

Assignee: Memorial Sloan Kettering Cancer Center

International Classification: C07K 16/18 (20060101); C07K 16/34 (20060101); C07K 16/30 (20060101); C07K 016/30 (); A61K 039/395 ()

Expiration Date: 10/30/2018